Showing posts with label bacterial resistant. Show all posts
Showing posts with label bacterial resistant. Show all posts

Monday, November 12, 2018

Be antibiotic aware during the antibiotic awareness week

World antibiotic awareness week is observed each November to increase global awareness about antibiotic resistance and unnecessary use of antibiotics among physicians, public and policymakers. This year the launch day is November 12 and various campaign and activities are planned globally to make the healthcare professionals and consumers aware of antimicrobial resistance (AMR.) 

AMR is an ever-rising menace and an urgent threat to public health. Antibiotic-resistant bacteria cause nearly one in five infections in developed countries. At least, 23,000 people die as a result of antibiotic resistance and nearly 2 million people get infected with antibiotic-resistant bacteria in the US alone.

If nothing is done, it is estimated that by 2050, more people will die because of bacterial infections that are resistant to available antibiotics as compared to cancer deaths. Besides promoting research and stricter prescribing laws, encouraging positive behavioral change to reduce the misuse of antibiotics remains one of the priorities in mitigating the spread of antibiotic resistance bacteria.

WHO has gathered information from 65 countries to track and document the consumption pattern of antibiotics around the world. The report notes that amoxicillin and amoxicillin/clavulanic acid – first or second-line treatments for common infections – are the most frequently used antibiotics worldwide.

Here are some of the key CDC messages for healthcare professionals to bring down the development of antibiotic resistance:

Always follow the clinical guidelines and remember the three “rights” for the antibiotic prescription–right antibiotic in the right dose for the right duration.

Shorten the antibiotic therapy to minimum effective duration to maximize the patient benefits and minimizing the side effects and development of resistance.

Protect your patient by only prescribing antibiotics when needed.

Educate your patients about the side effects and harms of antibiotic, their ineffectiveness in viral infection, what to do to feel better and when to contact your physician if they are not feeling good.

Make the patients and their caregiver aware of the signs and symptoms of sepsis.

Practice hand-hygiene at the clinics and hospitals to reduce cross infections.

If the patient is admitted, review the antibiotic regimen 48 to 72 hours after it is started based on the patient’s/resident’s clinical condition and microbiology culture results, and stop or change antibiotic orders as needed—a critical step in care.

Know about antibiotic resistance patterns in your practice areas and use the latest data to make informed prescribing decisions.

Sunday, September 25, 2016

Novel Investigational antibiotic for Gonorrhea holds a promise for future with 100% cure rate.

Gonorrhea is one of the most common STD in US. Recently public health officials have identified cluster of gonorrhea cases in Hawaii that show decreasing susceptibility to ceftriaxone and high level of resistance to azithromycin. [1] 

Currently a combination of ceftriaxone and azithromycin is the last available option for treating gonorrhea and investigators believe that they will run out of this option in near future. Left untreated, gonorrhea can lead to serious health problems including infertility, pelvic inflammatory disease and life-threatening ectopic pregnancy in women.

  • One third of the new gonorrhea infection are resistant to at least 1 drug.
  • It is the most common communicable disease in the US, with an estimated 820,000 new infections each year.
  • We are only left with 1 treatment option for gonorrhea out of 5 reported by CDC in 2006 due to development of resistance by the bacteria.

Hence, researchers have renewed interest in development of new drug for gonorrhea. At the 2016 STD Prevention Conference, researchers from Louisiana State University presented results of phase 2 clinical trials of experimental oral antibiotic that was safe and effective in treating uncomplicated gonorrhea. Unlike any other marketed antibiotic, the new drug dubbed as ETX0914 is a novel spiropyrimidinetrione, that acts by inhibiting deoxyribonucleic acid biosynthesis by accumulation of double strand cleavages. [3]

In a small clinical trial, a total of 179 participants (167 men and 12 women) were randomized approximately 70:70:40 to receive either 2000mg or 3000mg ETX0914 orally or 500mg ceftriaxone in a single intramuscular injection.

Patients were followed up for safety, microbiological and clinical cure rates. The drug was well tolerated with only mild gastrointestinal side effects.

All patients receiving 3g ETX0914 (47/47) and 98 percent of patients in the 2g group (48/49) were cured. 

The trials lead investigator Stephanie N. Taylor, M.D., professor of medicine and microbiology at Louisiana State University Health Sciences Center said “We are very pleased with these results and look forward to seeing ETX0914 advance through additional clinical studies.”

The combination therapy of azithromycin and ceftriaxone recommended by CDC is still effective, but “ will eventually fail” says  Jonathan Mermin, MD, director of the CDC's center for HIV/AIDS, viral hepatitis, STD, and TB prevention quotes "In the battle between humans and pathogens," he said, "gonorrhea is a formidable opponent."





[1] https://www.cdc.gov/nchhstp/newsroom/2016/2016-std-prevention-conference-press-release.html
[2] https://www.cdc.gov/stdconference/2016/highlights/arg.html
[3] https://cdc.confex.com/cdc/std2016/webprogram/Paper37739.html